Filing Flows › Volitionrx (VNRX) › Q1 2025
Volitionrx (VNRX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
Volitionrx (VNRX) reported revenue of $246K for the first quarter 2025 (Q1 2025), +44% from a year earlier and +29% from the quarter before.
Volitionrx, Q1 2025: revenue $246K (+44% year over year), net loss $5.5M, operating cash flow −$4.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $246K | +29% | +44% |
| Operating profit | −$5.5M | — | — |
| Net earnings | −$5.5M | — | — |
| Operating cash flow | −$4.3M | — | — |
What changed
Revenue was $246K in Q1 2025, up 44% year over year and up 29% from the previous quarter.
Operating costs exceeded revenue by $5.5M, an operating margin of -2241.1%. Total costs fell 33% while revenue rose 44%. The quarter ended with a net loss of $5.5M, narrower than the previous quarter's $5.9M loss. Minority interests bore $53K of it: to shareholders the quarter was a loss of $5.4M.
Operating cash flow was −$4.3M. Non-cash charges added back $252K of depreciation and amortization and $451K of share-based compensation. Working capital and other items added $475K. Capital expenditures of $2K exceeded it, leaving free cash flow of −$4.3M.
Questions
What was Volitionrx's revenue in the first quarter 2025?
Volitionrx (VNRX) reported revenue of $246K for the first quarter 2025 (Q1 2025), +44% from a year earlier and +29% from the quarter before.
Source: Volitionrx 10-Q on SEC EDGAR.